精品文档---下载后可任意编辑2 型糖尿病患者应用西格列汀的短期疗效观察及影响因素分析中期报告摘要：目的：探讨 2 型糖尿病患者应用西格列汀的短期疗效及影响因素。方法：选取 2 型糖尿病患者 68 例，随机分为西格列汀组和对比组，西格列汀组给予西格列汀片 1mg 口服，每日一次，对比组采纳常规治疗。治疗 8 周后，比较两组患者血糖、糖化血红蛋白（HbA1c）、血脂等指标的变化情况。结果：西格列汀组和对比组治疗结束时 HbA1c 分别为（6.8±1.3%）、（7.8±1.2%），两组比较差异有统计学意义（P<0.05）；西格列汀组和对比组治疗结束时空腹血糖分别为（7.4±1.1mmol/L）、（8.7±1.2mmol/L），两组比较差异有统计学意义（P<0.05）。西格列汀组治疗结束时总胆固醇、甘油三酯、低密度脂蛋白胆固醇与对比组比较无统计学意义（P>0.05）。结论：西格列汀能显著降低 2 型糖尿病患者 HbA1c 和空腹血糖水平，但对血脂水平的影响较弱。关键词：西格列汀；2 型糖尿病；疗效；影响因素Abstract:Objective: To investigate the short-term efficacy and influencing factors of sitagliptin in patients with type 2 diabetes.Methods: Sixty-eight patients with type 2 diabetes were randomly divided into a sitagliptin group and a control group. The sitagliptin group was given sitagliptin 1mg orally once a day, and the control group was treated with conventional therapy. After 8 weeks of treatment, changes in blood sugar, glycosylated hemoglobin (HbA1c), and blood lipids were compared between the two groups of patients.Results: At the end of treatment, the HbA1c values in the sitagliptin group and the control group were (6.8±1.3%) and (7.8±1.2%), respectively, and the difference between the two groups was statistically significant (P<0.05); the fasting blood sugar values in the sitagliptin group and the control group were (7.4±1.1mmol/L) and (8.7±1.2mmol/L), respectively, and 精品文档---下载后可任意编辑the difference between the two groups was statistically significant (P<0.05). The sitagliptin group had no significant differences in total cholesterol, triglycerides, and low-density lipoprotein cholesterol compared to the control group (P>0.05).Conclusion: Sitagliptin can significantly reduce the HbA1c and fasting blood sugar levels in patients with type 2 diabetes, but has a weak effect on blood lipids.Keywords: Sitagliptin; type 2 diabetes; efficacy; influencing factors.
